This trial is testing hormone therapy, using oral (Z)-Endoxifen, as a treatment for patients with invasive breast cancer.
This trial is treating patients with breast cancer.
This is a systemic therapy trial.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
An open label, pilot and expansion pharmacodynamic Study of (Z)-endoxifen in Patients with Invasive Breast Cancer Prior to Undergoing Mastectomy or Lumpectomy
Commercial Sponsor
Atossa Genetics, Inc.
Summary
In this trial, patients will be given 4mg/day of oral (Z)-Endoxifen, for a minimum of 21 days until the day before surgery (inclusive).
Recruiting Hospitals Read More